Patents by Inventor Johannes Caspar Mathias Elizabeth Bender

Johannes Caspar Mathias Elizabeth Bender has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220153930
    Abstract: The invention relates to a polyoxazoline (POx) copolymer comprising at least 20 oxazoline units, including at least 4 non-terminal oxazoline units that contain a calcium binding group selected from bisphosphonate, citrate, ethylenediaminetetraacetic acid (EDTA) and combinations thereof. The POx copolymers of the present invention exhibit very high affinity for calcium ions and are capable of forming hydrogels due to reversible cross-linking with Ca2+ ions. The POx copolymers offer the important advantage that they are bioresorbable. Calcium affinity, biodegradability and hydrogel characteristics of the POx copolymer can easily be tuned due to the fact that the POx can easily be derivatised along the entire polymeric backbone and not only at the end-groups. The POx copolymers of the invention may suitably be applied in a variety of biomedical applications, such as barrier membranes, patches, meshes, tapes, bone fixation devices, bone implants, (injectable) hydrogels, bone-setting glue and nanoparticles.
    Type: Application
    Filed: January 27, 2022
    Publication date: May 19, 2022
    Applicant: GATT TECHNOLOGIES B.V.
    Inventors: Sander Cornelis Gerardus LEEUWENBURGH, Jan Cornelis Maria VAN HEST, María José SÁNCHEZ-FERNÁNDEZ, Rosa Pilar FELIX LANAO, Joost OPSTEEN, Johannes Caspar Mathias Elizabeth BENDER
  • Publication number: 20220133949
    Abstract: The present invention relates to a haemostatic powder comprising at least 10 wt. % of particle agglomerates, said particle agglomerates having a diameter in the range of 1-500 ?m and comprising: electrophilic polyoxazoline particles containing electrophilic polyoxazoline carrying at least 3 reactive electrophilic groups that are capable of reacting with amine groups in blood under the formation of a covalent bond; and nucleophilic polymer particles containing a water-soluble nucleophilic polymer carrying at least 3 reactive nucleophilic groups that, in the presence of water, are capable of reacting with the reactive electrophilic groups of the electrophilic polyoxazoline under the formation of a covalent bond between the electrophilic polyoxazoline and the nucleophilic polymer. When applied to a bleeding site, the haemostatic powder of the present invention turns into a gel while at the same time binding to proteins present in the blood and on the surrounding tissue.
    Type: Application
    Filed: January 11, 2022
    Publication date: May 5, 2022
    Applicant: GATT TECHNOLOGIES B.V.
    Inventors: Abraham Reinier KEEREWEER, Rosa Pilar FÉLIX LANAO, Joost OPSTEEN, Johannes Caspar Mathias Elizabeth BENDER
  • Publication number: 20220133943
    Abstract: The invention relates to a biocompatible, flexible, haemostatic sheet comprising: a cohesive fibrous carrier structure comprising a three-dimensional interconnected interstitial space; and distributed within the interstitial space, a plurality of reactive polymer particles comprising (i) a water-soluble electrophilic polymer carrying at least 3 reactive electrophilic groups that are capable of reacting with amine groups in tissue and blood under the formation of a covalent bond and (ii) a nucleophilic cross-linking agent that contains at least two reactive nucleophilic groups that are capable of reacting with the reactive electrophilic groups of the electrophilic polymer under the formation of a covalent bond, said reactive polymer particles having a diameter in the range of 0.5-100 ?m and being present in an amount of at least 3% by weight of the fibrous carrier structure.
    Type: Application
    Filed: January 11, 2022
    Publication date: May 5, 2022
    Inventors: Abraham Reinier KEEREWEER, Rosa Pilar FÉLIX LANAO, Joost OPSTEEN, Johannes Caspar Mathias Elizabeth BENDER, Gerard LLANOS
  • Publication number: 20220133947
    Abstract: The invention relates to a biocompatible, flexible, haemostatic sheet comprising: a water-resistant cohesive fibrous carrier structure comprising a three-dimensional interconnected interstitial space, said fibrous carrier structure comprising fibres containing a nucleophilic polymer carrying reactive nucleophilic groups; and distributed within the interstitial space, a plurality of reactive polymer particles comprising a water-soluble electrophilic polymer carrying at least three reactive electrophilic groups that are capable of reacting with amine groups in tissue and blood, as well as with reactive nucleophilic groups of the nucleophilic polymer, under the formation of a covalent bond, said reactive polymer particles having a diameter in the range of 0.5-100 ?m and being present in an amount of at least 3% by weight of the fibrous carrier structure.
    Type: Application
    Filed: January 11, 2022
    Publication date: May 5, 2022
    Applicant: GATT TECHNOLOGIES B.V.
    Inventors: Abraham Reinier KEEREWEER, Rosa Pilar FÉLIX LANAO, Joost OPSTEEN, Johannes Caspar Mathias Elizabeth BENDER
  • Publication number: 20220133948
    Abstract: The invention provides a method for preparing tissue-adhesive sheets that may suitably be applied as an implantable haemostatic or sealing construct during surgical procedures, said method comprising: providing a fibrous sheet comprising a three-dimensional interconnected interstitial space; providing reactive polymer particles comprising a water-soluble electrophilic polymer carrying at least 3 reactive electrophilic groups that are capable of reacting with amine groups in blood under the formation of a covalent bond; placing the fibrous sheet and the reactive polymer particles between two electrodes; simultaneously subjecting the fibrous sheet and the reactive polymer particles to an electric field of 0.1 to 40 kV/mm to impregnate the interconnected interstitial space of the fibrous sheet with the reactive polymer particles.
    Type: Application
    Filed: January 11, 2022
    Publication date: May 5, 2022
    Applicant: GATT TECHNOLOGIES B.V.
    Inventors: Hubert Clemens PELLIKAAN, Abraham Reinier KEEREWEER, Johannes Caspar Mathias Elizabeth BENDER
  • Patent number: 10925996
    Abstract: A biocompatible, covalently cross-linked, polymer that is obtained by reacting an electrophilically activated polyoxazoline (EL-POX) with a nucleophilic cross-linking agent is disclosed. The EL-POX comprises m electrophilic groups; and the nucleophilic cross-linking agent comprises n nucleophilic groups, wherein the m electrophilic groups are capable of reacting with the n nucleophilic groups to form covalent bonds; wherein m?2, n?2 and m+n?5; wherein at least one of the m electrophilic groups is a pendant electrophilic group and/or wherein m?3; and wherein the EL-POX comprises an excess amount of electrophilic groups relative to the amount of nucleophilic groups contained in the nucleophilic cross-linking agent. Biocompatible medical products and kits comprising the cross-linked POX-polymers are also disclosed.
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: February 23, 2021
    Assignee: GATT TECHNOLOGIES BV
    Inventors: Richard Hoogenboom, Johannes Caspar Mathias Elizabeth Bender, Jan Cornelis Maria Van Hest
  • Patent number: 10751441
    Abstract: A process of preparing an adhesive haemostatic product is provided. The process comprises: (a) coating a porous solid substrate with a coating liquid that comprises an electrophilically activated polyoxazoline (EL-POX) and a solvent to produce a coated substrate; and (b) removing the solvent from the coated substrate. The EL-POX comprises at least 2 reactive electrophilic groups. The process enables the application of an EL-POX coating that leaves the pore structure of the substrate largely intact so that the ability of the porous substrate to absorb body fluids, such as blood, remains essentially unaffected. The EL-POX coated haemostatic product obtained by the present process has excellent adhesive properties due to the presence of electrophilic reactive groups that are capable of reacting with e.g. amine groups that are naturally present in tissue, under the formation of covalent bonds.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: August 25, 2020
    Assignee: GATT TECHNOLOGIES B.V.
    Inventors: Johannes Caspar Mathias Elizabeth Bender, Marcel Alexander Boerman
  • Publication number: 20190231923
    Abstract: A biocompatible, covalently cross-linked, polymer that is obtained by reacting an electrophilically activated polyoxazoline (EL-POX) with a nucleophilic cross-linking agent is disclosed. The EL-POX comprises m electrophilic groups; and the nucleophilic cross-linking agent comprises n nucleophilic groups, wherein the m electrophilic groups are capable of reacting with the n nucleophilic groups to form covalent bonds; wherein m?2, n?2 and m+n?5; wherein at least one of the m electrophilic groups is a pendant electrophilic group and/or wherein m?3; and wherein to the EL-POX comprises an excess amount of electrophilic groups relative to the amount of nucleophilic groups contained in the nucleophilic cross-linking agent. Biocompatible medical products and kits comprising the cross-linked POX-polymers are also disclosed.
    Type: Application
    Filed: April 8, 2019
    Publication date: August 1, 2019
    Applicant: GATT Technologies B.V.
    Inventors: Richard HOOGENBOOM, Johannes Caspar Mathias Elizabeth BENDER, Jan Cornelis Maria VAN HEST
  • Patent number: 10314936
    Abstract: A biocompatible, covalently cross-linked, polymer that is obtained by reacting an electrophilically activated polyoxazoline (EL-PDX) with a nucleophilic cross-linking agent is disclosed. The EL-PDX comprises m electrophilic groups; and the nucleophilic cross-linking agent comprises n nucleophilic groups, wherein the m electrophilic groups are capable of reacting with the n nucleophilic groups to form covalent bonds; wherein m?2, n?2 and m+n?5; wherein at least one of the m electrophilic groups is a pendant electrophilic group and/or wherein m?3; and wherein the EL-PDX comprises an excess amount of electrophilic groups relative to the amount of nucleophilic groups contained in the nucleophilic cross-linking agent. Biocompatible medical products and kits comprising the cross-linked PDX-polymers are also disclosed.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: June 11, 2019
    Assignee: GATT TECHNOLOGIES BV
    Inventors: Richard Hoogenboom, Johannes Caspar Mathias Elizabeth Bender, Jan Cornelis Maria Van Hest
  • Publication number: 20190125922
    Abstract: A process of preparing an adhesive haemostatic product is provided. The process comprises: (a) coating a porous solid substrate with a coating liquid that comprises an electrophilically activated polyoxazoline (EL-POX) and a solvent to produce a coated substrate; and (b) removing the solvent from the coated substrate. The EL-POX comprises at least 2 reactive electrophilic groups. The process enables the application of an EL-POX coating that leaves the pore structure of the substrate largely intact so that the ability of the porous substrate to absorb body fluids, such as blood, remains essentially unaffected. The EL-POX coated haemostatic product obtained by the present process has excellent adhesive properties due to the presence of electrophilic reactive groups that are capable of reacting with e.g. amine groups that are naturally present in tissue, under the formation of covalent bonds.
    Type: Application
    Filed: December 19, 2018
    Publication date: May 2, 2019
    Applicant: GATT Technologies B.V.
    Inventors: Johannes Caspar Mathias Elizabeth BENDER, Marcel Alexander BOERMAN
  • Patent number: 10232077
    Abstract: A process of preparing an adhesive haemostatic product is provided. The process comprises: (a) coating a porous solid substrate with a coating liquid that comprises an electrophilically activated polyoxazoline (EL-POX) and a solvent to produce a coated substrate; and (b) removing the solvent from the coated substrate. The EL-POX comprises at least 2 reactive electrophilic groups. The process enables the application of an EL-POX coating that leaves the pore structure of the substrate largely intact so that the ability of the porous substrate to absorb body fluids, such as blood, remains essentially unaffected. The EL-POX coated haemostatic product obtained by the present process has excellent adhesive properties due to the presence of electrophilic reactive groups that are capable of reacting with e.g. amine groups that are naturally present in tissue, under the formation of covalent bonds.
    Type: Grant
    Filed: October 5, 2015
    Date of Patent: March 19, 2019
    Assignee: GATT TECHNOLOGIES B.V.
    Inventors: Johannes Caspar Mathias Elizabeth Bender, Marcel Alexander Boerman
  • Publication number: 20180221531
    Abstract: A process of preparing an adhesive haemostatic product is provided. The process comprises: (a) coating a porous solid substrate with a coating liquid that comprises an electrophilically activated polyoxazoline (EL-POX) and a solvent to produce a coated substrate; and (b) removing the solvent from the coated substrate. The EL-POX comprises at least 2 reactive electrophilic groups. The process enables the application of an EL-POX coating that leaves the pore structure of the substrate largely intact so that the ability of the porous substrate to absorb body fluids, such as blood, remains essentially unaffected. The EL-POX coated haemostatic product obtained by the present process has excellent adhesive properties due to the presence of electrophilic reactive groups that are capable of reacting with e.g. amine groups that are naturally present in tissue, under the formation of covalent bonds.
    Type: Application
    Filed: October 5, 2015
    Publication date: August 9, 2018
    Applicant: GATT Technologies B.V.
    Inventors: Johannes Caspar Mathias Elizabeth BENDER, Marcel Alexander BOERMAN
  • Patent number: 9868822
    Abstract: One aspect of the invention relates to a biocompatible medical product comprising at least 1% by weight of dry matter of a covalently cross-linked polymer that is obtained by reacting a nucleophilically activated polyoxazoline (NU-PDX) with an electrophilic cross-linking agent other than an electrophilically activated polyoxazoline, said NU-PDX comprising m nucleophilic groups; and said electrophilic cross-linking agent comprising n electrophilic groups, wherein the m nucleophilic groups are capable of reaction with the n electrophilic groups to form covalent bonds; wherein m?2, n?2 and m+n?5; and wherein the NU-PDX comprises at least 30 oxazoline units in case the electrophilic cross-linking agent is an isocyanate. Also provided is a kit for producing the aforementioned biocompatible cross-linked polymer. The biocompatible cross-linked polymers according to the invention have excellent implant and/or sealing characteristics.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: January 16, 2018
    Assignee: GATT Technologies B.V.
    Inventors: Johannes Caspar Mathias Elizabeth Bender, Richard Hoogenboom, Jan Cornelis Maria Van Hest, Harry Van Goor
  • Patent number: 9770527
    Abstract: One aspect of the invention relates to a biocompatible, covalently cross-linked, polymer that is obtained by reacting an electrophilically activated polyoxazoline (EL-POX) with a nucleophilic cross-linking agent, said electrophilically activated POX comprising m electrophilic groups; and said nucleophilic cross-linking agent comprising n nucleophilic groups, wherein the m electrophilic groups are capable of reaction with the n nucleophilic groups to form covalent bonds; wherein m?2, n?2 and m+n?5; wherein at least one of the m electrophilic groups is a pendant electrophilic group and/or wherein m?3; and wherein the EL-POX comprises an excess amount of electrophilic groups relative to the amount of nucleophilic groups contained in the nucleophilic cross-linking agent. The invention further relates to biocompatible medical products comprising such a cross-linked POX-polymer. Also provided is a kit for producing a biocompatible, cross-linked POX-polymer.
    Type: Grant
    Filed: January 2, 2012
    Date of Patent: September 26, 2017
    Assignee: Bender Analytical Holding B.V.
    Inventors: Richard Hoogenboom, Johannes Caspar Mathias Elizabeth Bender, Jan Cornelis Maria van Hest
  • Publication number: 20170266337
    Abstract: A biocompatible, covalently cross-linked, polymer that is obtained by reacting an electrophilically activated polyoxazoline (EL-PDX) with a nucleophilic cross-linking agent is disclosed. The EL-PDX comprises m electrophilic groups; and the nucleophilic cross-linking agent comprises n nucleophilic groups, wherein the m electrophilic groups are capable of reacting with the n nucleophilic groups to form covalent bonds; wherein m?2, n?2 and m+n?5; wherein at least one of the m electrophilic groups is a pendant electrophilic group and/or wherein m?3; and wherein the EL-PDX comprises an excess amount of electrophilic groups relative to the amount of nucleophilic groups contained in the nucleophilic cross-linking agent. Biocompatible medical products and kits comprising the cross-linked PDX-polymers are also disclosed.
    Type: Application
    Filed: June 8, 2017
    Publication date: September 21, 2017
    Applicant: Bender Analytical Holding B.V.
    Inventors: Richard HOOGENBOOM, Johannes Caspar Mathias Elizabeth BENDER, Jan Cornelis Maria VAN HEST
  • Publication number: 20160319075
    Abstract: One aspect of the invention relates to a biocompatible medical product comprising at least 1% by weight of dry matter of a covalently cross-linked polymer that is obtained by reacting a nucleophilically activated polyoxazoline (NU-PDX) with an electrophilic cross-linking agent other than an electrophilically activated polyoxazoline, said NU-PDX comprising m nucleophilic groups; and said electrophilic cross-linking agent comprising n electrophilic groups, wherein the m nucleophilic groups are capable of reaction with the n electrophilic groups to form covalent bonds; wherein m?2, n?2 and m+n?5; and wherein the NU-PDX comprises at least 30 oxazoline units in case the electrophilic cross-linking agent is an isocyanate. Also provided is a kit for producing the aforementioned biocompatible cross-linked polymer. The biocompatible cross-linked polymers according to the invention have excellent implant and/or sealing characteristics.
    Type: Application
    Filed: July 14, 2016
    Publication date: November 3, 2016
    Applicant: Bender Analytical Holding B.V.
    Inventors: Johannes Caspar Mathias Elizabeth BENDER, Richard HOOGENBOOM, Jan Cornelis Maria VAN HEST, Harry VAN GOOR
  • Patent number: 9416228
    Abstract: One aspect of the invention relates to a biocompatible medical product comprising at least 1% by weight of dry matter of a covalently cross-linked polymer that is obtained by reacting a nucleophilically activated polyoxazoline (NU-POX) with an electrophilic cross-linking agent other than an electrophilically activated polyoxazoline, said NU-POX comprising m nucleophilic groups; and said electrophilic cross-linking agent comprising n electrophilic groups, wherein the m nucleophilic groups are capable of reaction with the n electrophilic groups to form covalent bonds; wherein m?2, n?2 and m+n?5; and wherein the NU-POX comprises at least 30 oxazoline units in case the electrophilic cross-linking agent is an isocyanate. Also provided is a kit for producing the aforementioned biocompatible cross-linked polymer. The biocompatible cross-linked polymers according to the invention have excellent implant and/or sealing characteristics.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: August 16, 2016
    Assignee: Bender Analytical Holding B.V.
    Inventors: Johannes Caspar Mathias Elizabeth Bender, Richard Hoogenboom, Jan Cornelis Maria Van Hest, Harry Van Goor
  • Patent number: 9308175
    Abstract: One aspect of the invention relates to a pharmaceutical dosage unit for sublingual, buccal, pulmonary or oral administration, said dosage unit having a weight of 20-500 mg and comprising 1-80 wt. % of a microgranulate that is distributed throughout a solid hydrophilic matrix; said microgranulate being characterized in that it: has a volume weighted average diameter of 5-100 m; contains at least 0.01 wt. %, preferably at least 0.1 wt. % of one or more water-insoluble pharmaceutically active substances; contains at least 10 wt. %, preferably at least 20 wt. % of an emulsifier component; and is capable of forming a micro-emulsion upon contact with saliva or water. The dosage units of the present invention achieve the inherent benefits of oral delivery while at the same time realizing a high transmucosal absorption rate of the cannabinoids contained therein.
    Type: Grant
    Filed: September 14, 2007
    Date of Patent: April 12, 2016
    Assignee: Echo Pharmaceuticals B.V.
    Inventors: Hubert Clemens Pellikaan, Pieter Sebastiaan Vermeulen, Johannes Caspar Mathias Elizabeth Bender, Geert Feye Woerlee
  • Publication number: 20150045507
    Abstract: One aspect of the invention relates to a biocompatible medical product comprising at least 1% by weight of dry matter of a covalently cross-linked polymer that is obtained by reacting a nucleophilically activated polyoxazoline (NU-POX) with an electrophilic cross-linking agent other than an electrophilically activated polyoxazoline, said NU-POX comprising m nucleophilic groups; and said electrophilic cross-linking agent comprising n electrophilic groups, wherein the m nucleophilic groups are capable of reaction with the n electrophilic groups to form covalent bonds; wherein m?2, n?2 and m+n?5; and wherein the NU-POX comprises at least 30 oxazoline units in case the electrophilic cross-linking agent is an isocyanate. Also provided is a kit for producing the aforementioned biocompatible cross-linked polymer. The biocompatible cross-linked polymers according to the invention have excellent implant and/or sealing characteristics.
    Type: Application
    Filed: March 15, 2013
    Publication date: February 12, 2015
    Applicant: Bender Analytical Holding B.V.
    Inventors: Johannes Caspar Mathias Elizabeth Bender, Richard Hoogenboom, Jan Cornelis Maria Ven Hest, Harry Van Goor
  • Patent number: 8927524
    Abstract: The present invention relates to ready-to-use sterile, alginate-based, aqueous compositions for medical use. More particularly, the invention relates to an aqueous composition for medical use that has been sterilized by heat sterilization and having a viscosity at 25° C. of at least 300 cP) (Helipath® T F spindle, 100 rpm at 25° C.), said composition having a pH in the range of 6.5-7.5; containing 0.5-10 wt. % of an alginate salt; and further containing 10-500 mM of one or more dissolved C2-C7 mono- or dicarboxylates that are optionally substituted with up to 2 hydroxyl groups. The alginate-based composition of the present invention has excellent storage stability and is easy to manufacture. The alginate-based aqueous compositions of the present invention can advantageously be used, for instance, to prevent adhesions between a healing trauma site and adjacent surrounding tissue. These compositions can further be used in implants or in pharmaceutical preparations for oral administration.
    Type: Grant
    Filed: March 8, 2011
    Date of Patent: January 6, 2015
    Assignee: Bender Analytical Holding B.V.
    Inventors: Johannes Caspar Mathias Elizabeth Bender, Hubert Clemens Pellikaan